Failure of 3,4-diaminopyridine to reverse conduction block in inflammatory demyelinating neuropathies.
3,4-Diaminopyridine was administered to 6 patients with inflammatory demyelinating neuropathies in whom partial conduction block was demonstrable. Four had Guillain-Barré syndrome and 2 had chronic inflammatory demyelinating neuropathy. Nerve conduction studies were performed before the administration of a single oral dose of 3,4-diaminopyridine, and at regular intervals thereafter. Neither resolution of conduction block nor clinical benefit were seen.
Bergin
P S
PS
National Hospital for Neurology and Neurosurgery, London, United Kingdom.
Miller
D H
DH
Hirsch
N P
NP
Murray
N M
NM
D015761:4-Aminopyridine / Q000031:analogs & derivatives* / Q000494:pharmacology; D000077770:Amifampridine; D002908:Chronic Disease; D003711:Demyelinating Diseases / Q000503:physiopathology*; D006801:Humans; D009431:Neural Conduction / Q000187:drug effects*; D011129:Polyradiculoneuropathy / Q000503:physiopathology*; D015221:Potassium Channels / Q000187:drug effects / Q000502:physiology; D013997:Time Factors
D015221:Potassium Channels; D015761:4-Aminopyridine; D000077770:Amifampridine